1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Antacids Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Antacids Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Antacids Market Regional Analysis
6.2 North America Antacids Market Revenue 2017-2027 (US$ Million)
6.3 North America Antacids Market Forecast Analysis
7. North America Antacids Market Analysis – by Dosage Form
7.1 Tablet
- 7.1.1 Overview
- 7.1.2 Tablet: North America Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Liquid
- 7.2.1 Overview
- 7.2.2 Liquid: North America Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. North America Antacids Market Analysis – by Drug Class
8.1 Proton Pump Inhibitors
- 8.1.1 Overview
- 8.1.2 Proton Pump Inhibitors: North America Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 H2 Antagonist
- 8.2.1 Overview
- 8.2.2 H2 Antagonist: North America Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.3 Acid Neutralizers
- 8.3.1 Overview
- 8.3.2 Acid Neutralizers: North America Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. North America Antacids Market Analysis – by Distribution Channel
9.1 Hospital Pharmacy
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacy: North America Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Retail Pharmacy
- 9.2.1 Overview
- 9.2.2 Retail Pharmacy: North America Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Online Pharmacy
- 9.3.1 Overview
- 9.3.2 Online Pharmacy : North America Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. North America Antacids Market – North America Analysis
10.1 Overview
10.2 North America
- 10.2.1 North America Antacids Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.2.1.1 North America Antacids Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 US:
North America Antacids Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.1.1 US: North America Antacids Market Breakdown, by Dosage Form
- 10.2.1.1.2 US: North America Antacids Market Breakdown, by Drug Class
- 10.2.1.1.3 US: North America Antacids Market Breakdown, by Distribution Channel
- 10.2.1.2 Canada:
North America Antacids Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.2.1 Canada: North America Antacids Market Breakdown, by Dosage Form
- 10.2.1.2.2 Canada: North America Antacids Market Breakdown, by Drug Class
- 10.2.1.2.3 Canada: North America Antacids Market Breakdown, by Distribution Channel
- 10.2.1.3 Mexico :
North America Antacids Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.3.1 Mexico : North America Antacids Market Breakdown, by Dosage Form
- 10.2.1.3.2 Mexico : North America Antacids Market Breakdown, by Drug Class
- 10.2.1.3.3 Mexico : North America Antacids Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Bayer AG
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 GlaxoSmithKline plc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Takeda Pharmaceutical Company Limited
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Sun Pharmaceutical Industries Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Sanofi
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Boehringer Ingelheim International GmbH
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Dr. Reddy's Laboratories
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Pfizer Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Reckitt Benckiser Group Plc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Procter & Gamble
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Get Free Sample For North America Antacids Market
